MaxCyte (MXCT) Set to Announce Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The company had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $15.60 million. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Performance

Shares of MXCT opened at $3.77 on Monday. MaxCyte has a 52 week low of $2.45 and a 52 week high of $5.55. The stock has a market capitalization of $394.12 million, a price-to-earnings ratio of -10.19 and a beta of 1.36. The stock has a fifty day moving average of $4.13 and a 200-day moving average of $4.36.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. BTIG Research dropped their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. William Blair reiterated an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th. Finally, Stephens reaffirmed an “overweight” rating and set a $11.00 target price on shares of MaxCyte in a research report on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.